Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis
Angela Dispenzieri(Mayo Clinic), David Murray(Unknown), Francis K. Buadi, Morie A. Gertz(Medical University of South Carolina), Nelson Leung(WinnMed), Dragan Jevremović(Mayo Clinic in Arizona), Robert A. Kyle(Mayo Clinic), Shaji Kumar(Mayo Clinic), Ronald S. Go(Mayo Clinic), Prashant Kapoor, Yi L. Hwa, Mindy Kohlhagen(Mayo Clinic), Steven R. Zeldenrust, A C Fonder(Mayo Clinic), Rahma Warsame, Surendra Dasari(Mayo Clinic in Arizona), S. Vincent Rajkumar(WinnMed), Wilson I. Gonsalves(Mayo Clinic in Arizona), Taxiarchis Kourelis(Mayo Clinic in Arizona), Martha Q. Lacy(Mayo Clinic), Eli Muchtar(Mayo Clinic), Suzanne R. Hayman, John A. Lust, Miriam Hobbs, Bonnie K. Arendt(Mayo Clinic), David Dingli
Cited by 44
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k